


References:

1. National Institute of Diabetes and Digestive Kidney Disease. Porphyrin. Updated July 2020. <https://www.niddk.nih.gov/health-information/liver-disease/porphyria>
2. Wahlin S, Srikanthan N, Hamre Borge, Harper P, Brun A. Protection from phototoxic injury during surgery and endoscopy in erythropoietic protoporphyria. *Liver Transpl.* 2008;14(9):1340-1346. doi:10.1002/lt.21527
3. Balwani M. Erythropoietic protoporphyria and X-linked protoporphyria: Pathophysiology, genetics, clinical manifestations, and management. *Mol Genet Metab.* 2019;128(3):298–303. doi:10.1016/j.ymgme.2019.01.020
4. Balwani M, Nalk H, Anderson KE, et al. Clinical, biochemical, and genetic characterization of North American patients with erythropoietic protoporphyria and X-linked protoporphyria. *JAMA Dermatol.* 2017;153(8):789-796. doi:10.1001/jamadermatol.2017.1557
5. Kaye E, Levin J, Blank I, et al. Efficiency of opaque photoprotective agents in the visible light range. *Arch Dermatol.* 1991;127(3):351-355. doi:10.1001/archderm.1991.01680030071009
6. Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for erythropoietic protoporphyria. *N Engl J Med.* 2015;373(1):48-59. doi:10.1056/NEJMoa1411481
7. Anstey AV, Hift RJ. Liver disease in erythropoietic protoporphyria: insights and implications for management. *Postgrad Med.* 2007;83(986):739-748. doi:10.1136/gut.2006.097576
8. Seth A, Badminton M, Russel S, et al. Liver transplantation for porphyria: Who, when and how. *Liver Transpl.* 2007; 13(9):1219-1227. doi:10.1002/lt.21261
9. McGuire BM, Bonkovsky HL, Carithers RL, et al. Liver transplantation for erythropoietic protoporphyria liver disease. *Liver Transpl.* 2005; 11:1590-1596. doi:10.1002/lt.20620
10. Balwani M, Bonkovsky H, Belongie K, et al. Erythropoietic protoporphyria: Phase 2 clinical trial results evaluating the safety and effectiveness of dersimelagon (MT-7117), an oral MC1R agonist. *Blood.* 2020;136(1): 51.
11. ClinicalTrials.gov. Study to evaluate efficacy, safety, and tolerability of MT-7117 in subjects with erythropoietic protoporphyria or X-linked protoporphyria. Updated April 25, 2022. <https://clinicaltrials.gov/ct2/show/NCT04402489>
12. ClinicalTrials.gov. Effect of oral cimetidine in the protoporphyrias. Updated May 16, 2022. <https://clinicaltrials.gov/ct2/show/NCT05020184>
13. ClinicalTrials.gov. Oral iron for erythropoietic protoporphyrias (EPP). Updated September 11, 2020. <https://clinicaltrials.gov/ct2/show/NCT02979249>
14. Suzuki T, Kawno Y, Matsumoto A, et al. Melanogenic effect of dersimelagon (MT-7117), a novel oral melanocortin 1 receptor agonist. *Skin Health Dis.* 2021;29(1):e78. doi:10.1002/ski2.78



15. Mirmiran A, Schmitt C, Lefebvre T, et al. Erythroid-progenitor-targeted gene therapy using bifunctional TFR1 ligand-peptides in human erythropoietic protoporphyria. *Am J Hum Genet.* 2019;104:341-347. doi:10.1016/j.ajhg.2018.12.021
16. Tu JH, Sheu SL, Teng JM. Novel treatment using cimetidine for erythropoietic protoporphyria in children. *JAMA Dermatol.* 2016;152:1258. doi:10.1001/jamadermatol.2016.2303